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Background: We evaluated whether or not PET or PET/CT using L-methyl-[11C]-methionine (MET) can allow for the
early prediction of local recurrence and metastasis, as well as the prognosis (disease-specific survival), in patients
with adenoid cystic carcinoma of the head and neck treated by carbon ion beam radiotherapy.
Methods: This was a retrospective cohort study of sixty-seven patients who underwent a MET-PET or PET/CT study
prior to and one month after the completion of carbon ion radiotherapy (CIRT). The minimum follow-up period for
survivors was 12 months. The MET accumulation of the tumor was evaluated using the semiquantitative tumor to
normal tissue ratio (TNR). A univariate analysis was conducted using the log-rank method, and the Cox model was
used in a multivariate survival regression analysis.
Results: The average TNR prior to and following treatment was 4.8 (±1.5) and 3.0 (±1.3), respectively, showing a
significant decrease following treatment. In the univariate analysis, a high TNR prior to treatment (TNRpre) was a
significant factor for predicting the occurrence of metastasis and the disease-specific survival. A high TNR following
treatment (TNRpost) was a significant factor for predicting the development of local recurrence. The residual ratio
of TNR changes (TNRratio) seemed to be less useful than the TNRpre. In the multivariate analysis, the TNRpost and
tumor size were the factors found to significantly influence the risk of local recurrence. The TNRpre, TNRratio and
tumor size were all significant factors influencing the occurrence of metastasis. Regarding the disease-specific
survival, the TNRpre and age were the only factors with a significant influence on the outcome.
Conclusions: The TNRpre was a factor that was significantly related to the occurrence of metastasis and the
disease-specific survival after CIRT for adenoid cystic carcinoma of the head and neck. The TNRpost was a factor
that was significantly related to the development of local recurrence. Thus, MET-PET or PET/CT can be useful for
predicting or determining the therapeutic efficacy of CIRT.
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Adenoid cystic carcinomas are malignant tumors gener-
ated from the secretory epithelial cells of the salivary
glands, accounting for about 10% of all salivary gland tu-
mors. They are relatively rare tumors, representing less
than 1% of all malignant tumors in the head and neck
region [1,2]. Although their development is slow, they
have a strong tendency for local invasion and locally
recur at a high frequency. They are also characterized by
the frequent occurrence of metastasis during the clinical
course over a long period of time [2-6]. Radical excision
by surgery has been the primary treatment option, how-
ever, wide-range excision can be difficult due to the
complicated anatomical structure in the head and neck
region. A decrease in quality of life following surgery is
also unavoidable due to the loss of oral functions and
aesthetic issues due to formal changes in the tissues.
Adenoid cystic carcinomas have low radiation sensitivity,
and the local control rate is unsatisfactory with radiation
therapy using conventional X-rays [7]. Furthermore,
there has been no clear evidence regarding the effects of
chemotherapy [4,8].
Heavy-particle therapy
Carbon ions are a type of heavy ion associated with high
linear energy transfer (LET) radiation with high relative
biological effectiveness (RBE). The biological characteris-
tics of these ions include that there is little recovery
observed following sub-lethal damage (SLD) [9], and
smaller differences in sensitivity due to the phase in the
cell cycle [10] and due to the oxygen concentration (low
OER: oxygen enhancement ratio) [11] compared to low
LET radiation, such as X-rays or proton beams. The
physical characteristics of these carbon ions include their
having a high relative dose, called a Bragg peak, which
reaches about 15 cm deep from the body surface. Conse-
quently, carbon ions have excellent efficacy when used
in focused dose concentrations, in addition to allowing
for treatment at a good dose distribution with fewer side
effects on normal tissues [12]. Taking these characteris-
tics into consideration, it is believed that carbon ions
can also provide an effective therapeutic method for can-
cers that are resistant to conventional radiation.
L-methyl [C-11]-methionine (MET)
The amino acid metabolism in malignant cells is related
to various catabolic processes associated with tumor
growth [13]. MET is a neutral essential amino acid that
plays a key role in cancer cell metabolism [14]. MET is a
necessary amino acid for protein and polyamine synthe-
sis, as well as transmethylation reactions. Because of
their enhanced levels of these reactions, the uptake of
MET into cancer cells is enhanced [15-17]. This metabol-
ism can be visualized by positron emission tomography(PET) using radiolabeled MET. However, the use of MET
imaging is restricted to PET centers with an in-house
cyclotron and radiochemistry facility because of the short
half-life (20 min) of C-11.
Carbon ion radiotherapy and PET for head and neck
cancers
In our institute, a Phase I/II carbon ion radiotherapy
(CIRT) trial has been conducted in patients with
unresectable head and neck cancers, and 669 head and
neck tumors had been treated with CIRT as of March
2010 [18-20]. The three-year local control rate of ade-
noid cystic carcinomas of the head and neck in patients
treated with carbon ion radiotherapy (CIRT) was 82%,
and the five-year survival rate was 68% [19,20]. A MET-
PET (or PET/CT) study was performed to evaluate the
tumor prior to and following heavy-particle therapy. In
bone and soft tissue sarcomas and chordomas, we have
reported that the development of local recurrence could
be predicted using the rate of decrease in MET accumu-
lation prior to and following heavy-particle therapy
[21,22]. In choroidal malignant melanomas, although
there were no changes in the long-term tumor size ob-
served in MRI studies following heavy-particle therapy,
decreases in MET accumulation were observed in most
cases from six months or more after treatment [23]. The
usefulness of MET-PET in evaluating heavy-particle
therapy for adenocarcinoma of the head and neck has
previously been examined [24]. The present study was a
retrospective cohort study to investigate the accuracy of
MET-PET (or PET/CT) for predicting the efficacy of
heavy-particle therapy against primary adenoid cystic
carcinomas of the head and neck.
Methods
Patients
CIRT for head and neck tumors is used in patients for
whom a surgical resection is difficult, or for patients
who reject surgery and wish to undergo CIRT. Patients
who had undergone chemotherapy within four weeks
prior to CIRT and for whom radiotherapy had already
been performed at the tumor site were not eligible for
CIRT [19]. In this study, we included only the patients
who were histologically diagnosed to have primary
adenoid cystic carcinoma and for whom CIRT was
performed. All of the patients in this study received
MET-PET or PET/CT examinations both prior to and
following CIRT. We excluded patients who had received
chemotherapy prior to CIRT, even if it was more than
four weeks prior, from this study. Patients whose cause
of death was unknown were also excluded from this
study. The institutional ethics committee (National Insti-
tute of Radiological Sciences) approved the study, and
written informed consent was obtained. There were very
Table 1 Patient characteristics (n = 67 patients)














Nasal cavity 7 10%
Paranasal sinus 21 31%
Salivary gland 9 13%
Oral cavity 14 21%
Pharyngolarynx 10 15%
Orbita 2 3%
Lacrimal gland 2 3%
Lacrimal sac 1 2%
Ear canal 1 2%
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and neck, so it took a long time to collect a sufficient
number of cases. There were 67 primary cases that re-
ceived CIRT during the period between October 1995
and December 2009, and that underwent a MET-PET
(or PET/CT) study prior to and following treatment.
The subjects consisted of 27 males and 40 females, with
an average age of 54 ± 15 years old (15–84 years old). Pa-
tients were staged according to the fourth edition of the
TNM staging system (International Union Against Can-
cer; UICC, 1987) [25], and there was one case of T1 (2%),
six cases of T2 (9%), nine cases of T3 (13%) and 51 cases
of T4 (76%) disease. The average follow-up period follow-
ing treatment was 50.8 ± 33.8 months (10–180 months),
and the minimum follow-up period for survivors was
12 months. The first follow-up examinations, including
MET-PET, CT and MRI, were performed four weeks after
the completion of CIRT. Further CT or MRI studies
followed every two or three months for the first two years
and every four to six months for the rest of the follow-up
period. The tumors were evaluated according to the
World Health Organization definitions [26]. The develop-
ment of metastasis and local recurrence during the
follow-up period were diagnosed based on the imaging in-
formation obtained by periodic CT or MRI showing an
obvious increase in the tumor or nodule size, i.e. progres-
sive disease was defined as a more than 25% increase in
the product of the perpendicular diameters of the tumor.
A summary of the cases is provided in Table 1.
Carbon ion radiotherapy protocol
A heavy particle accelerator system and the biophysical
characteristics of the carbon ion beam have been de-
scribed in a previous report [12]. The protocol used for
CIRT has also been described in detail in a previous re-
port [19]. CIRT for malignant tumors in the head and
neck region is targeted at advanced cases in which surgi-
cal excision is determined to be difficult, or cases in
which the patients refuse surgery and prefer CIRT. The
cases in which chemotherapy was performed within four
weeks prior to treatment, or in which radiation therapy
had already been performed at the treatment site were
excluded from the indications for treatment. Table 2
shows the regimen of CIRT used in this study.
PET and PET/CT studies
MET with a high specific activity was produced by the
standard technique using a method modified from the
synthesis reported by Langstrom et al. [27]. The MET
studies for adenoid cystic carcinomas of the head and
neck were carried out with a PET device over the period
between October 1995 and September 2007. The studies
were changed to a PET/CT device, and patients were ex-
amined using the new device between January 2003 andFebruary 2010. In the PET study, whole-body scanners
(ECAT EXACT HR+ and ECAT EXACT 47; Siemens
CTI, Knoxville, TN, USA) were used. In the PET/CT
study, whole-body PET/CT scanners (Biograph duo and
Biograph 16; Siemens CTI, Knoxville, TN and Aquiduo;
Toshiba Medical Systems Corporation, Otawara-shi,
Tochigi-ken) were used. The ECAT EXACT HR+, ECAT
EXACT 47, Biograph duo, Biograph 16 and Aquiduo
were used to scan 29, 9, 10, 7 and 12 patients, respect-
ively. The same PET device as was used for the MET-PET
study prior to the treatment was also used to carry out the
study following the treatment so that the results could be
easily compared. With the ECATs and Biograph duo,
emission data corrected for random events, dead time and
attenuation were reconstructed by filtered backprojection
using a Ramp filter with a cut-off frequency of 0.4,
Table 2 Carbon ion radiotherapy regimens






Nasal cavity 7 (10%) 52.8-70.8 3.3-4.4
Paranasal sinus 21 (31%) 52.8-70.8 3.3-4.4
Salivary gland 9 (13%) 57.6-64.0 3.6-4.0
Oral cavity 14 (21%) 57.6-64.0 3.6-4.1
Pharyngolarynx 10 (15%) 57.6-64.8 3.6-4.0
Orbita 2 (3%) 57.6, 64.0 3.6, 4.0
Lacrimal gland 2 (3%) 57.6, 64.0 3.6, 4.0
Lacrimal sac 1 (2%) 57.6 57.6
Ear canal 1 (2%) 52.8 52.8
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Aquiduo instruments, emission data with the corrections
were reconstructed by OSEM using 16 subsets, four itera-
tions and a Gaussian filter (FWHM 8.0 mm), followed by
decay correction.
A PET or PET/CT study was carried out prior to the
start of CIRT (average 11 ± 7.3 days; 0–34 days) and
approximately one month after the completion of the
treatment (average 30 ± 9.4 days; 11–69 days). The pa-
tients fasted for at least four hours prior to the study.
For the emission data, on average, 703 ± 63 MBq (19 ±
1.7 mCi) or 518–884 MBq (14–24 mCi) of MET was ad-
ministered intravenously, and collection was started after
23 minutes. Regarding the difference in the sensitivity in
the PET scanners, static emission scans were performed
for 30 min using the ECAT EXACT HR+ and for
15 min by the ECAT EXACT 47 for each bed position,
respectively [21,22,28]. For the PET/CT study, prior to a
PET emission scan, an unenhanced helical CT scan (tube
voltage: 120 kV, tube current range: 10-300 mA) was
performed with a pitch of 0.5 s/rotation. CT images
were reconstructed with a filtered back projection algo-
rithm (512 × 512 matrix size, and a slice thickness of
2.0 mm) and the μ-map data for attenuation correction
were calculated from the CT data. The CT scan was
performed from the calvarium to the femoral region,
and the PET emission data were collected for these re-
gions. The emission scan was performed for three mi-
nutes per bed, and was performed for seven to nine
beds. PET and PET/CT images were interpreted in con-
sensus by a nuclear medicine specialist physician (with
more than 25 years of experience in nuclear medicine
and PET) and two oral and maxillofacial surgeons who
were certified as PET nuclear medicine specialists (five
and six years of PET experience, respectively).
Statistical analysis
The survival period was defined as the time period from
the start of CIRT until death or completion of this study.The univariate analysis was conducted using a log-rank
test that compared the associations among the clinical,
radiographic and pathological parameters with the sur-
vival curves between two groups. The Cox model was
used in a multivariate survival regression analysis, while
adjusting the survival comparisons for various factors
that otherwise influenced survival. The hazard ratio was
calculated from this model.
Tumor accumulation was evaluated using a semi-
quantitative TNR (tumor to normal tissue ratio) evalu-
ation, which was calculated using the SUN Ultra 60 and
SUN Blade 2500 PET software programs (version 7.22;
Siemens CTI, Knoxville, TN, USA), and VOX BASE II
(version 2.69j; J-MAC System, Inc, Sapporo, Hokkaido,
Japan). The TNR was calculated using the following for-
mula: TNR = [mean counts per pixel of tumor regions
of interest]/[mean counts per pixel of normal tissue re-
gions of interest]. Two normal tissue regions of interest
(ROIs) were set in the muscles of the posterior region of
the neck, and the mean counts for these ROIs were used
to calculate the TNR. In some cases, ROIs were difficult
to determine by PET, but adding anatomical information
obtained by CT or MRI could allow them to be set.
The univariate and multivariate analyses were carried
out regarding the TNR prior to treatment (TNRpre),
TNR following treatment (TNRpost) and the residual ratio
of TNR changes (TNRratio), as well as the age, gender
and tumor size (three clinical factors). The univariate ana-
lysis was conducted to identify the statistically significant
relationships between the TNRs and treatment outcomes,
and to determine the optimal cut-off values for dividing
the patients into two groups. Then, using the cut-off
values derived from the univariate analysis, the multivari-
ate analysis was conducted for the relationships that were
found to be statistically significant in the univariate ana-
lysis. The TNRratio was calculated as follows; [TNRpre]/
[TNRpost] × 100 (%). A difference of p < 0.05 was consid-
ered to be significant. To define the two groups in the
Kaplan-Meier analysis, the most appropriate cut-off levels
were determined to be the midpoint of the range, so that
the lowest p value was obtained in each statistical analysis
[29]. Forty millimeters was employed as a cut-off value for
the tumor size (peak dimension), because this value is
regarded to be the boundary between T2 and T3 tumors
of the head and neck in many sites, such as the oral cavity,
large salivary gland, oropharynx and hypopharynx [25].
The statistical analyses were conducted using the Statview
software program (version 5.0; SAS Institute Inc, Cary,
North Carolina, USA) [30].
Results
Clinical results and PET imaging
Among the 67 total patients, 21 patients (31%) died due
to cancer progression (cancer death). Twenty-one patients
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and metastasis during the follow-up period, respectively.
The tumor size (radius of the maximum length) before
treatment averaged 49 ± 16 mm (range, 20–87 mm). All
adenoid cystic carcinomas of the head and neck were visu-
ally distinguishable from the surrounding tissues by the
MET-PET and PET/CT studies prior to heavy-particle
therapy. In several cases, the tumors were close to the oral
cavity mucosa, but their boundaries were relatively diffi-
cult to define due to the influence of physiological accu-
mulation, in which introducing anatomical information
from CT or MRI could identify the tumors. Representative
cases in which CIRT was particularly effective are shown
in Figure 1. The average values of the TNRpre, TNRpost,
as well as the TNRratio were 4.8 ± 1.5 (2.6-9.0), 3.0 ± 1.3
(1.0-7.0) and 66 ± 26% (19-150%), respectively, demon-
strating that there were significant differences in the aver-
age values of the TNRpre and TNRpost (paired-t test,
p < 0.0001) [Figure 2]. The five-year disease-specific sur-
vival rate was 69%, and the 10-year disease-specific sur-
vival rate was 45%.
Univariate analysis
In the univariate analysis, the group with a high TNRpre
showed significantly more metastasis compared to theFigure 1 A 49-year-old female who received 57.6 GyE for paranasal s
imaging (MRI) showed a 53 × 44 mm mass in the paranasal sinus region. b
high accumulation mass in the region shown in the MRI. c. MRI revealed tum
image after the treatment demonstrated decreased MET uptake.group with a lower value (cut-off value = 5.6, p < 0.0001),
and also showed a poorer prognosis (disease-specific
survival) (cut-off value = 5.6, p < 0.0001). Groups with a
high TNRpost value showed significantly more local
recurrence compared to the group with a lower value
(cut-off value = 3.5, p < 0.005). Regarding the TNRratio,
there were significantly more occurrences of metastasis
in the group with a low TNRratio (cut-off value = 60%,
p < 0.01), and as would be expected, the disease-specific
survival was poorer in this group (cut-off value = 80%,
p < 0.05); however, a significant negative correlation
(Spearman rank correlation coefficient, ρ = −0.32, p <
0.02) was observed between the TNRratio and the
TNRpre, with a tendency for the TNRratio to be lower
in cases with a high TNRpre. The above results are sum-
marized in the Table 3 and Figures 3 and 4.
Multivariate analysis
A multivariate analysis (Cox proportional hazard model)
was conducted using the age, gender, tumor size,
TNRpre, TNRpost and TNRratio. Three clinical factors
were added to investigate whether or not the TNRpre,
TNRpost and TNRratio can be used as predictive factors
for local recurrence, metastasis and disease-specific sur-
vival. That is, the average age of 54 years old and ainus cancer. The arrows indicate the tumors. a. Magnetic resonance
. A methionine (MET)-PET/CT image prior to treatment demonstrated a
or shrinkage 44 days after carbon ion radiotherapy. d. The MET-PET/CT
Figure 2 A comparison of the tumor to normal tissue ratio
(TNR) prior to and following CIRT. The average values of the TNR
prior to treatment and after treatment were 4.8 ± 1.5 (2.6-9.0) and
3.0 ± 1.3 (1.0-7.0), respectively, and the difference between them was
significant (paired-t test, p < 0.0001).
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were used as cut-off values. Regarding the TNRpre, a
multivariate analysis was conducted for metastasis and
disease-specific survival in which significant differences
had been observed in the univariate analysis. A cut-off
value of 5.6 was set for each TNRpre. Regarding the
TNRpost, a multivariate analysis was conducted for local
recurrence, in which significant differences had been
observed in the univariate analysis. A cut-off value of 3.5
was set for the TNRpost. Regarding the TNRratio, a
multivariate analysis was conducted for metastasis and
disease-specific survival, in which significant differences
had been observed in the univariate analysis. The cut-off
values were set at 60% for metastasis and 80% for
disease-specific survival.Table 3 Results of a univariate analysis
Recurrences Metastasis Survival
TNR prior to treatment
(P value)
- ≥5.6 ≥5.6





Residual ratio of TNR (P value) ‐ <60% <80%
(p < 0.01)* (p < 0.05)*
*Significant difference (p < 0.05, log-lank).Regarding the development of local recurrence in the
investigation using the TNRpost and three clinical
factors, the TNRpost (p < 0.04) and tumor size (p < 0.03)
were identified as influential factors. In the investigation
of metastasis using the TNRpre and three clinical
factors, the TNRpre (p < 0.002) was the only influential
factor. In the investigation of metastasis using the
TNRratio and three clinical factors, the TNRratio
(p < 0.04) and tumor size (p < 0.03) were both identified
as influential factors.
With regard to the disease-specific survival in the
investigation using the TNRpre and three clinical factors,
the TNRpre (p < 0.02) and age (p < 0.03) were identified
as influential factors, while in the investigation using the
TNRratio and three clinical factors, the tumor size
(p < 0.04), age (p < 0.05) and gender (p < 0.02) were all
identified as influential factors affecting the disease-
specific survival. The above results are summarized in
Tables 4, 5 and 6.
Discussion
Primary adenoid cystic carcinomas of the head and neck
are relatively rare tumors [1,2], with slow development,
but which have a strong tendency for local invasion,
leading a frequency of metastasis and a poor prognosis
[2-6]. Currently, surgery and postoperative irradiation
have been the most common therapeutic methods used
to treat these cancers. According to a review by Dodd
et al., the efficacy of chemotherapy is highly variable.
Regimens with platinating agents, anthracyclines and al-
kylating agents have shown the most consistent reaction
rates, with efficacy rates ranging from 25-33% [8]. Spiro
et al. reported that local recurrence was observed in
62% and metastasis in 38% of patients in an investigation
of 196 cases of salivary gland primary adenoid cystic
carcinomas (surgery only, 188 cases; radiation only, 8
cases) [5]. Khan et al. reported the outcomes of various
treatments, and the overall rate of local recurrence was
12-52% and the rate of metastasis was 19-52% [3]. In
our investigation, local recurrence developed in 31% of
the 67 cases and metastasis was observed in 40% of
cases; however, considering that 76% of the 67 cases
were in stage T4, it should be noted that the local con-
trol by CIRT was relatively high compared to that of
other therapeutic methods.
It has been reported that the development of local re-
currence or metastasis 10 years following treatment is
not rare in patients with adenoid cystic carcinomas [31],
with one case of lung metastasis among our cases occur-
ring 132 months after treatment. It is believed that strict
follow-up is required over a long time period. Fordice
et al. have reported that, in 160 cases of primary adenoid
cystic carcinoma of the head and neck for which surgery
alone or surgery/radiation combination therapy were
Figure 3 The results of a univariate analysis using the Kaplan-Meier method. a. The five-year local recurrence rates demonstrated a
significant difference between the two groups divided by the TNR following treatment (the cut-off value was 3.5, p < 0.005). b. The five-year
metastasis rates demonstrated a significant difference between the two groups divided by the TNR prior to treatment (the cut-off value was 5.6,
p < 0.0001). c. The five-year metastasis rates demonstrated a significant difference between the two groups divided by the residual ratio of the
TNR (the cut-off value was 60%, p < 0.01). d. The five-year disease-specific survival rates demonstrated a significant difference between the two
groups divided by the TNR prior to treatment (the cut-off value was 5.6, p < 0.0001). e. The five-year disease-specific survival rates demonstrated a
significant difference between the two groups divided by the residual ratio of the TNR (the cut-off value was 80%, p < 0.05).
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10-year survival rate was 67.4% [32]. A review by Khan
et al. reported that the five-year survival rate was 67-73%
and the 10-year survival rate was 44-51% [3]. In our study,
the five-year survival rate was 69% and the 10-year sur-
vival rate was 45%, which was approximately the same as
those reported in the other studies.
No other report using PET targeting primary adenoid
cystic carcinoma of the head and neck has been pub-
lished. However, Lindholm et al. performed MET-PET
prior to and following treatment with radiation therapyfor cancer of the head and neck in 15 cases (SCC in 13
cases, ACC in one case and plasmocytoma in one case)
and reported that the MET accumulation following
treatment was significantly related to the histological
effect [33]. Chesnay et al. showed that MET-PET accumu-
lation after the completion of one course of chemotherapy
for hypopharynx squamous cancer was significantly corre-
lated with a reduction in the tumor mass, as measured by
MRI at the completion of three courses of chemotherapy.
Although there were no significant differences between
the groups with a good/poor effect observed by the MET-
Figure 4 The correlation between the residual ratio of the TNR
and the TNR prior to CIRT. There was a significant negative
correlation observed between the residual ratio of the TNR changes
and the TNR prior to treatment (Spearman rank correlation
coefficient, ρ = −0.32, p < 0.02).
Table 5 Prognostic factors including following treatment
in the patients using multivariate analysis
Variable Multivariate
CI CI p value HR
Recurrence
TNR following treatment (≥3.5 vs. <3.5) 0.142 0.907 0.0303 0.359
Tumor size (>40 vs. ≤40) 0.092 0.852 0.0249 0.280
Age (≥54 vs. <54) 0.250 1.751 0.4056 0.662
Gender (male vs. female) 0.219 1.387 0.2061 0.552
CI confidence interval, HR hazard ratio.
Table 6 Prognostic factors including the residual ratio of
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survival rates, which were 83% and 57% [34]. Hasebe et al.
carried out a statistical (univariate and multivariate ana-
lysis) investigation regarding the use of MET-PET to pre-
dict the therapeutic efficacy of CIRT for 39 head and neck
adenocarcinoma patients, and their multivariate analysis
revealed that the TNRpre was a significant factor influen-
cing the metastasis and disease-specific survival, while the
TNR following the treatment was associated with the localTable 4 Prognostic factors including prior to treatment in
the patients using multivariate analysis
Variable Multivariate
CI CI p value HR
Metastasis
TNR prior to treatment (≥5.6 vs. <5.6) 0.089 0.557 0.0013 0.222
Tumor size (>40 vs. ≤40) 0.166 1.082 0.0725 0.423
Age (≥54 vs. <54) 0.339 1.827 0.5766 0.787
Gender (male vs. female) 0.342 2.003 0.6743 0.827
Survival
TNR prior to treatment (≥5.6 vs. <5.6) 0.090 0.751 0.0128 0.259
Tumor size (>40 vs. ≤40) 0.129 1.325 0.1373 0.414
Age (≥54 vs. <54) 0.097 0.843 0.0232 0.287
Gender (male vs. female) 0.181 1.700 0.3023 0.555
CI confidence interval, HR hazard ratio.recurrence, metastasis and disease-specific survival, and
the change in accumulation was associated with the devel-
opment of metastasis and the disease-specific survival.
Consequently, it was reported that MET-PET allowed for
a prediction of the therapeutic efficacy [24]. These refer-
ences seem to suggest that MET-PET is potentially useful
for determining the therapeutic efficacy of radiation ther-
apy and chemotherapy.
As a result of our multivariate analysis, the TNRpost
based on the MET accumulation and the tumor size
were found to be significantly influential factors in terms
of local recurrence. In terms of indices regarding MET
accumulation that are associated with the occurrence of
metastasis, the TNRpre and TNRratio were identified
as the significantly influential factors. With regard to
the disease-specific survival, the TNRpre and age were
the significantly influential factors, while the tumor
size, patient age and gender were also influential in
other combinations.
Kokemueller et al. pointed out that the tumor size as
an important factor for predicting local recurrence [6].
Spiro et al. pointed out that the size of the primary focusTNR changes prior to and following treatment in the
patients using multivariate analysis
Variable Multivariate
CI CI p value HR
Metastasis
Residual ratio of TNR (≥60% vs. <60%) 1.051 5.229 0.0374 2.344
Tumor size (>40 vs. ≤40) 0.135 0.863 0.0230 0.342
Age (≥54 vs. <54) 0.350 1.889 0.6311 0.814
Gender (male vs. female) 0.222 1.119 0.0914 0.499
Survival
Residual ratio of TNR (≥80% vs. <80%) 0.652 8.254 0.1939 2.319
Tumor size (>40 vs. ≤40) 0.097 0.927 0.0364 0.300
Age (≥54 vs. <54) 0.112 0.980 0.0459 0.332
Gender (male vs. female) 0.113 0.805 0.0166 0.302
CI confidence interval, HR hazard ratio.
Residual ratio of TNR: residual ratio of tracer uptake change prior to and
following carbon ion radiotherapy.
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http://www.ro-journal.com/content/8/1/143was an influential factor on metastasis [1]. Jones et al.
have suggested that the prognosis was significantly bet-
ter for T1 + T2 patients, with a 10-year survival rate of
80% for T1 + T2, while it was only 30% for T3 + T4 cases
[35]. In our results, the tumor size was also a signifi-
cantly influential factor for local recurrence, in addition
to metastasis and disease-specific survival. Moreover,
Jones et al. [35] reported that males with primary ade-
noid cystic carcinomas of the head and neck had a sig-
nificantly better prognosis than females, while our
results suggested that the five-year survival rate was 53%
for males and 78% for females, indicating that females
had a better disease-specific survival in our patient
cohort. The TNRpre was a significant factor predicting
both the development of metastasis and the disease-
specific survival. Similarly, the TNRpost was a significant
factor for predicting local recurrence. However, there
was a significant negative correlation observed between
the TNRratio and TNRpre. That is, cases with a low
TNRratio were likely to have a high TNRpre (i.e. negative
correlation), and therefore, to have a tendency toward
more frequent occurrence of metastasis. It is believed that
the TNRratio is less useful than the TNRpre.
In our present investigation, it was suggested that it
was possible to predict the effects of CIRT using MET-
PET (or PET/CT). Based on these results, it is expected
that PET studies will be useful for selecting an optimal
individualized treatment strategy, for example, by
introducing a strict short-term follow-up or active
combination therapy with chemotherapy, etc., when an
increased risk of metastasis is identified in cases with a
high TNRpre. The determination of the effect of CIRT
using MET-PET (or PET/CT) is also expected to con-
tribute to clinical studies of other malignant tumors
being carried out at our institute.Conclusion
In patients with adenoid cystic carcinomas of the head
and neck on which CIRT was performed, MET-PET (or
PET/CT) performed prior to treatment could predict the
development of future metastasis and the disease-specific
survival. MET-PET (or PET/CT) performed following
treatment was able to predict the development of local re-
currence. Thus, MET-PET or PET/CT is useful for deter-
mining the therapeutic efficacy of CIRT.
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